奥沙利铂（OX）化疗可能会导致癌症幸存者出现长期的感觉运动障碍。这些障碍通常被认为是OX引起的感觉传入神经退行性病变所致，即长程再生感觉性神经病变。然而，最近的临床前研究发现运动神经元的肌肉前感受器编码和运动神经元放电存在功能缺陷。这些前感受性运动神经回路的功能缺陷可以很容易地影响肌肉的伸展反射，而肌肉伸展反射是运动协调的基础。鉴于肌肉前感受器分布在骨骼肌中的各个部位，伸展反射缺陷可能是广泛存在的，包括在退行性感觉神经病变不太明显的近端区域。所有以往关于化疗相关反射变化的研究都集中在远端关节，导致结果可能受退行性感觉神经病变的影响，而不是更具体的感觉运动回路变化。我们的研究通过测量16名癌症幸存者和16名健康对照者肩部肌肉的伸展反射来扩展这项早期研究。完成了手部感觉神经的传导研究以检测远端感觉神经病变。我们发现，与预期的结果相反，癌症幸存者和健康对照者的肩部肌肉短潜伏期伸展反射（幅度和潜伏期）没有显著差异。我们的结果可能与人类与临床前实验模式之间的差异有关，包括测试肢体或物种的差异等等。确定这些差异的来源对于完整了解奥沙利铂化疗如何导致长期感觉运动障碍至关重要。

Oxaliplatin (OX) chemotherapy can lead to long-term sensorimotor impairments in cancer survivors. The impairments are often thought to be caused by OX-induced progressive degeneration of sensory afferents known as length-dependent dying-back sensory neuropathy. However, recent preclinical work has identified functional defects in the encoding of muscle proprioceptors and in motoneuron firing. These functional defects in the proprioceptive sensorimotor circuitry could readily impair muscle stretch reflexes, a fundamental building block of motor coordination. Given that muscle proprioceptors are distributed throughout skeletal muscle, defects in stretch reflexes could be widespread, including in the proximal region where dying-back sensory neuropathy is less prominent. All previous investigations on chemotherapy-related reflex changes focused on distal joints, leading to results that could be influenced by dying-back sensory neuropathy rather than more specific changes to sensorimotor circuitry. Our study extends this earlier work by quantifying stretch reflexes in the shoulder muscles in 16 cancer survivors and 16 healthy controls. Conduction studies of the sensory nerves in hand were completed to detect distal sensory neuropathy. We found no significant differences in the short-latency stretch reflexes (amplitude and latency) of the shoulder muscles between cancer survivors and healthy controls, contrasting with the expected differences based on the preclinical work. Our results may be linked to differences between the human and preclinical testing paradigms including, among many possibilities, differences in the tested limb or species. Determining the source of these differences will be important for developing a complete picture of how OX chemotherapy contributes to long-term sensorimotor impairments.